ENANTA PHARMACEUTICALS INC (ENTA) Fundamental Analysis & Valuation

NASDAQ:ENTA • US29251M1062

Current stock price

12.51 USD
-0.49 (-3.77%)
At close:
12.51 USD
0 (0%)
After Hours:

This ENTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ENTA Profitability Analysis

1.1 Basic Checks

  • In the past year ENTA has reported negative net income.
  • In the past year ENTA has reported a negative cash flow from operations.
  • ENTA had negative earnings in each of the past 5 years.
  • ENTA had a negative operating cash flow in each of the past 5 years.
ENTA Yearly Net Income VS EBIT VS OCF VS FCFENTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

1.2 Ratios

  • ENTA has a better Return On Assets (-21.71%) than 74.47% of its industry peers.
  • With a decent Return On Equity value of -56.51%, ENTA is doing good in the industry, outperforming 61.12% of the companies in the same industry.
Industry RankSector Rank
ROA -21.71%
ROE -56.51%
ROIC N/A
ROA(3y)-29.64%
ROA(5y)-27.87%
ROE(3y)-92.79%
ROE(5y)-67.21%
ROIC(3y)N/A
ROIC(5y)N/A
ENTA Yearly ROA, ROE, ROICENTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTA Yearly Profit, Operating, Gross MarginsENTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ENTA Health Analysis

2.1 Basic Checks

  • ENTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ENTA has been increased compared to 1 year ago.
  • Compared to 5 years ago, ENTA has more shares outstanding
  • The debt/assets ratio for ENTA is higher compared to a year ago.
ENTA Yearly Shares OutstandingENTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
ENTA Yearly Total Debt VS Total AssetsENTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • ENTA has an Altman-Z score of -0.62. This is a bad value and indicates that ENTA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ENTA (-0.62) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.82 indicates that ENTA is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ENTA (0.82) is worse than 72.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z -0.62
ROIC/WACCN/A
WACC8.3%
ENTA Yearly LT Debt VS Equity VS FCFENTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • ENTA has a Current Ratio of 4.44. This indicates that ENTA is financially healthy and has no problem in meeting its short term obligations.
  • ENTA's Current ratio of 4.44 is in line compared to the rest of the industry. ENTA outperforms 52.03% of its industry peers.
  • A Quick Ratio of 4.44 indicates that ENTA has no problem at all paying its short term obligations.
  • The Quick ratio of ENTA (4.44) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.44
Quick Ratio 4.44
ENTA Yearly Current Assets VS Current LiabilitesENTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ENTA Growth Analysis

3.1 Past

  • ENTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.35%, which is quite impressive.
  • The Revenue has been growing slightly by 0.58% in the past year.
  • The Revenue for ENTA have been decreasing by -11.82% on average. This is quite bad
EPS 1Y (TTM)35.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)0.58%
Revenue growth 3Y-8.83%
Revenue growth 5Y-11.82%
Sales Q2Q%9.76%

3.2 Future

  • ENTA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.68% yearly.
  • ENTA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.57% yearly.
EPS Next Y36.81%
EPS Next 2Y20.21%
EPS Next 3Y14.16%
EPS Next 5Y12.68%
Revenue Next Year2.52%
Revenue Next 2Y-1.13%
Revenue Next 3Y1.36%
Revenue Next 5Y18.57%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ENTA Yearly Revenue VS EstimatesENTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
ENTA Yearly EPS VS EstimatesENTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENTA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTA. In the last year negative earnings were reported.
  • Also next year ENTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTA Price Earnings VS Forward Price EarningsENTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTA Per share dataENTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ENTA's earnings are expected to grow with 14.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.21%
EPS Next 3Y14.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ENTA Dividend Analysis

5.1 Amount

  • ENTA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENTA Fundamentals: All Metrics, Ratios and Statistics

ENANTA PHARMACEUTICALS INC

NASDAQ:ENTA (3/20/2026, 4:04:33 PM)

After market: 12.51 0 (0%)

12.51

-0.49 (-3.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09
Earnings (Next)05-11
Inst Owners91.37%
Inst Owner Change46.24%
Ins Owners4.87%
Ins Owner Change1.47%
Market Cap363.04M
Revenue(TTM)66.98M
Net Income(TTM)-71.54M
Analysts82.86
Price Target20.66 (65.15%)
Short Float %7.92%
Short Ratio9.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.73%
Min EPS beat(2)16.46%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)27.18%
Min EPS beat(4)8.52%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)16.79%
EPS beat(12)9
Avg EPS beat(12)14.76%
EPS beat(16)11
Avg EPS beat(16)11.21%
Revenue beat(2)1
Avg Revenue beat(2)3%
Min Revenue beat(2)-7.07%
Max Revenue beat(2)13.07%
Revenue beat(4)2
Avg Revenue beat(4)3.32%
Min Revenue beat(4)-8.27%
Max Revenue beat(4)15.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.5%
Revenue beat(12)6
Avg Revenue beat(12)-1.79%
Revenue beat(16)7
Avg Revenue beat(16)-3.18%
PT rev (1m)5.88%
PT rev (3m)6.58%
EPS NQ rev (1m)20.65%
EPS NQ rev (3m)34.5%
EPS NY rev (1m)23.27%
EPS NY rev (3m)21.97%
Revenue NQ rev (1m)9.99%
Revenue NQ rev (3m)9.99%
Revenue NY rev (1m)4.87%
Revenue NY rev (3m)4.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.42
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-3.2
EYN/A
EPS(NY)-2.13
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS2.31
BVpS4.36
TBVpS4.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.71%
ROE -56.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.64%
ROA(5y)-27.87%
ROE(3y)-92.79%
ROE(5y)-67.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.15%
Cap/Sales 6.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.44
Quick Ratio 4.44
Altman-Z -0.62
F-Score4
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)477.27%
Cap/Depr(5y)305.21%
Cap/Sales(3y)19.24%
Cap/Sales(5y)12.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y36.81%
EPS Next 2Y20.21%
EPS Next 3Y14.16%
EPS Next 5Y12.68%
Revenue 1Y (TTM)0.58%
Revenue growth 3Y-8.83%
Revenue growth 5Y-11.82%
Sales Q2Q%9.76%
Revenue Next Year2.52%
Revenue Next 2Y-1.13%
Revenue Next 3Y1.36%
Revenue Next 5Y18.57%
EBIT growth 1Y33.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y81.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.68%
OCF growth 3YN/A
OCF growth 5YN/A

ENANTA PHARMACEUTICALS INC / ENTA Fundamental Analysis FAQ

What is the fundamental rating for ENTA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENTA.


Can you provide the valuation status for ENANTA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ENANTA PHARMACEUTICALS INC (ENTA). This can be considered as Overvalued.


Can you provide the profitability details for ENANTA PHARMACEUTICALS INC?

ENANTA PHARMACEUTICALS INC (ENTA) has a profitability rating of 1 / 10.